Reduced Food Intake is the Major Contributor to the Protective Effect of Rimonabant on Islet in Established Obesity-Associated Type 2 Diabetes
1
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Purpose: Although the presence of cannabinoid type 1 (CB1) receptor in islets has been reported, the major contributor to the protective effect of rimonabant on islet morphology is unknown. We determined whether the protective effect of rimonabant on pancreatic islet morphology is valid in established diabetes and also whether any effect was independent of decreased food intake. Materials and Methods: After diabetes was confirmed, Otsuka Long-Evans Tokushima Fatty rats, aged 32 weeks, were treated with rimonabant (30 mg/kg/d, rimonabant group) for 6 weeks. Metabolic profiles and islet morphology of rats treated with rimonabant were compared with those of controls without treatment (control group), a pair-fed control group, and rats treated with rosiglitazone (4 mg/kg/d, rosiglitazone group). Results: Compared to the control group, rats treated with rimonabant exhibited reduced glycated albumin levels (p<0.001), islet fibrosis (p<0.01), and improved glucose tolerance (p<0.05), with no differences from the pair-fed control group. The retroperitoneal adipose tissue mass was lower in the rimonabant group than those of the pair-fed control and rosiglitazone groups (p<0.05). Rimonabant, pair-fed control, and rosiglitazone groups showed decreased insulin resistance and increased adiponectin, with no differences between the rimonabant and pair-fed control groups. Conclusion: Rimonabant had a protective effect on islet morphology in vivo even in established diabetes. However, the protective effect was also reproduced by pair-feeding. Thus, the results of this study did not support the significance of islet CB1 receptors in islet protection with rimonabant in established obesity-associated type 2 diabetes.
Abstract
Purpose: Although the presence of cannabinoid type 1 (CB1) receptor in islets has been reported, the major contributor to the protective effect of rimonabant on islet morphology is unknown. We determined whether the protective effect of rimonabant on pancreatic islet morphology is valid in established diabetes and also whether any effect was independent of decreased food intake. Materials and Methods: After diabetes was confirmed, Otsuka Long-Evans Tokushima Fatty rats, aged 32 weeks, were treated with rimonabant (30 mg/kg/d, rimonabant group) for 6 weeks. Metabolic profiles and islet morphology of rats treated with rimonabant were compared with those of controls without treatment (control group), a pair-fed control group, and rats treated with rosiglitazone (4 mg/kg/d, rosiglitazone group). Results: Compared to the control group, rats treated with rimonabant exhibited reduced glycated albumin levels (p<0.001), islet fibrosis (p<0.01), and improved glucose tolerance (p<0.05), with no differences from the pair-fed control group. The retroperitoneal adipose tissue mass was lower in the rimonabant group than those of the pair-fed control and rosiglitazone groups (p<0.05). Rimonabant, pair-fed control, and rosiglitazone groups showed decreased insulin resistance and increased adiponectin, with no differences between the rimonabant and pair-fed control groups. Conclusion: Rimonabant had a protective effect on islet morphology in vivo even in established diabetes. However, the protective effect was also reproduced by pair-feeding. Thus, the results of this study did not support the significance of islet CB1 receptors in islet protection with rimonabant in established obesity-associated type 2 diabetes.
참고문헌 (28)
- Koh EH, "Peroxisome proliferator-activated receptor (PPAR)-alpha activation prevents diabetes in OLETF rats: comparison with PPAR-gamma activation", Diabetes, 52, pp.2331~2337 (2003)
- Duvivier VF, "Beneficial effect of a chronic treatment with rimonabant on pancreatic function and beta-cell morphology in Zucker Fatty rats", Eur J Pharmacol, 616, pp.314~320 (2009)
- Finegood DT, "Beta-cell mass dynamics in Zucker diabetic fatty rats. Rosiglitazone prevents the rise in net cell death", Diabetes, 50, pp.1021~1029 (2001)
- Janiak P, "Blockade of cannabinoid CB1 receptors improves renal function, metabolic profile, and increased survival of obese Zucker rats", Kidney Int, 72, pp.1345~1357 (2007)
- Nissen SE, "Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes", N Engl J Med, 356, pp.2457~2471 (2007)
- Singh S, "Long-term risk of cardiovascular events with rosiglitazone: a meta-analysis", JAMA, 298, pp.1189~1195 (2007)
- Lewis JD, "Risk of bladder cancer among diabetic patients treated with pioglitazone: interim report of a longitudinal cohort study", Diabetes Care, 34, pp.916~922 (2011)
- Piccinni C, "Assessing the association of pioglitazone use and bladder cancer through drug adverse event reporting", Diabetes Care, 34, pp.1369~1371 (2011)
- Christensen R, "Efficacy and safety of the weight-loss drug rimonabant: a meta-analysis of randomised trials", Lancet, 370, pp.1706~1713 (2007)
- Bermudez-Silva FJ, "The endocannabinoid system, eating behavior and energy homeostasis: the end or a new beginning?", Pharmacol Biochem Behav, 95, pp.375~382 (2010)
- Pavon FJ, "Antiobesity effects of the novel in vivo neutral cannabinoid receptor antagonist 5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-3-hexyl-1H-1,2,4-triazole--LH 21", Neuropharmacology, 51, pp.358~366 (2006)
- Salamone JD, "Cannabinoid CB1 receptor inverse agonists and neutral antagonists: effects on food intake, food-reinforced behavior and food aversions", Physiol Behav, 91, pp.383~388 (2007)
- Tam J, "Peripheral CB1 cannabinoid receptor blockade improves cardiometabolic risk in mouse models of obesity", J Clin Invest, 120, pp.2953~2966 (2010)
- Nakata M, "Cannabinoids inhibit insulin secretion and cytosolic Ca2+ oscillation in islet beta-cells via CB1 receptors", Regul Pept, 145, pp.49~53 (2008)
- Vilches-Flores A, "CB1 cannabinoid receptor expression is regulated by glucose and feeding in rat pancreatic islets", Regul Pept, 163, pp.81~87 (2010)
- Getty-Kaushik L, "The CB1 antagonist rimonabant decreases insulin hypersecretion in rat pancreatic islets", Obesity, 17, pp.1856~1860 (2009)
- Li C, "Cannabinoid receptor agonists and antagonists stimulate insulin secretion from isolated human islets of Langerhans", Diabetes Obes Metab, 13, pp.903~910 (2011)
- Kawano K, "Spontaneous long-term hyperglycemic rat with diabetic complications. Otsuka Long-Evans Tokushima Fatty (OLETF) strain", Diabetes, 41, pp.1422~1428 (1992)
- Ishida K, "Which is the primary etiologic event in Otsuka Long-Evans Tokushima Fatty rats, a model of spontaneous non-insulin-dependent diabetes mellitus, insulin resistance, or impaired insulin secretion?", Metabolism, 44, pp.940~945 (1995)
- Watanabe T, "Rimonabant ameliorates insulin resistance via both adiponectin-dependent and adiponectin-independent pathways", J Biol Chem, 284, pp.1803~1812 (2009)
- Yang SJ, "Activation of peroxisome proliferator-activated receptor gamma by rosiglitazone increases sirt6 expression and ameliorates hepatic steatosis in rats", PLoS One, 6, pp.e17057~ (2011)
- Kouzuma T, "An enzymatic method for the measurement of glycated albumin in biological samples", Clin Chim Acta, 324, pp.61~71 (2002)
- Kouzuma T, "Study of glycated amino acid elimination reaction for an improved enzymatic glycated albumin measurement method", Clin Chim Acta, 346, pp.135~143 (2004)
- Li C, "Expression and function of cannabinoid receptors in mouse islets", Islets, 2, pp.293~302 (2010)
- Bermúdez-Silva FJ, "Presence of functional cannabinoid receptors in human endocrine pancreas", Diabetologia, 51, pp.476~487 (2008)
- Vettor R, "The role of the endocannabinoid system in lipogenesis and fatty acid metabolism", Best Pract Res Clin Endocrinol Metab, 23, pp.51~63 (2009)
- Mølhøj S, "Effect of the cannabinoid receptor-1 antagonist rimonabant on lipolysis in rats", Eur J Pharmacol, 646, pp.38~45 (2010)
- Moran TH, "Disordered food intake and obesity in rats lacking cholecystokinin A receptors", Am J Physiol, 274(3), pp.R618~R625 (1998)